Pharmaceutical patents case clarifies first authorisation

Supplementary Protection Certificate appeal dismissed on reference to European case law

Pharmaceutical company Neurim appealed a decision to turn down its application for a Supplementary Protection Certificate. The higher court dismissed the appeal, and its judgment clarifies the European definition of first authorisation of a medicinal product.